title: The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
abstract: Several methods are now available for the laboratory assessment of activated protein C resistance (APCR). In this study, we evaluated two activated partial thromboplastin time-based assays [Coatest activated protein C (APC) and Diagen protein C activator (PCA)], with and without predilution of test plasma in factor V-deficient plasma (FVdp) and an amidolytic assay (Immuno Ltd, Vienna, Austria). Testing plasmas from normal volunteers who had received 1-deamino-8-D-arginine vasopressin (DDAVP) also assessed the effect of elevated factor VIII on APCR. In the unmodified clotting tests, the Coatest kit gave overlapping results for normal and heterozygous FV:Q506 samples; some FV:Q506 samples on oral anticoagulant therapy (OAT) were misclassified as normal, and some normal samples with high factor VIII levels would be classified as APC resistant. The unmodified Diagen kit correctly classified these three types of sample, but had the disadvantage that prolonged PCA clotting times gave serious problems with instrument end-point detection. Both kits modified by diluting the samples in FVdp correctly classified all the samples, as well as samples from patients with lupus anticoagulant (LA) and patients receiving heparin. The Immunochrom kit correctly classified the normal and FV:Q506 samples, but would have misclassified most normal persons on OAT as well as some patients with LA or receiving heparin therapy as APC resistant.
authors: Haematology Department, University College London Hospitals, UK. a.chitolie@ucl.ac.uk
authors: A
authors: A
authors: Chitolie
authors: A S
authors: AS
authors: Lawrie
authors: I J
authors: IJ
authors: Mackie
authors: P
authors: P
authors: Harrison
authors: S J
authors: SJ
authors: Machin
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D000284:Administration, Oral; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D002863:Chromogenic Compounds / Q000378:metabolism; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D023381:Endpoint Determination; D005165:Factor V / Q000737:chemistry / Q000235:genetics; D005166:Factor V Deficiency / Q000097:blood* / Q000235:genetics; D005169:Factor VIII / Q000032:analysis*; D005188:False Negative Reactions; D005838:Genotype; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000502:physiology; D010314:Partial Thromboplastin Time; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D011933:Reagent Kits, Diagnostic; D012016:Reference Values; D012680:Sensitivity and Specificity
chemical_list: D000925:Anticoagulants; D002863:Chromogenic Compounds; D016682:Lupus Coagulation Inhibitor; D011486:Protein C; D017293:Protein S; D011933:Reagent Kits, Diagnostic; C119012:factor V Cambridge; C095381:factor V Leiden; D005165:Factor V; D005169:Factor VIII; D006493:Heparin; D003894:Deamino Arginine Vasopressin